Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

Abstract Background The identification of novel therapeutic strategies to overcome resistance to the MEK inhibitor trametinib in mutant KRAS lung adenocarcinoma (LUAD) is a challenge. This study analyzes the effects of trametinib on Id1 protein, a key factor involved in the KRAS oncogenic pathway, a...

Descrición completa

Detalles Bibliográficos

Principais autores:	Ander Puyalto, María Rodríguez-Remírez, Inés López, Irati Macaya, Elizabeth Guruceaga, María Olmedo, Anna Vilalta-Lacarra, Connor Welch, Sergio Sandiego, Silvestre Vicent, Karmele Valencia, Alfonso Calvo, Ruben Pio, Luis E. Raez, Christian Rolfo, Daniel Ajona, Ignacio Gil-Bazo
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2024-04-01
Series:	Molecular Cancer
Assuntos:	KRAS-mutant lung adenocarcinoma Trametinib Id1 PD-1 inhibition PD-L1 Proteasome
Acceso en liña:	https://doi.org/10.1186/s12943-024-01991-3
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!